Cargando…
Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes
BACKGROUND: Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in various non-ischemic cardiomyopathies. Ischemic LGE lesions are prevalent in diabetes (DM), but non-ischemic LGE lesions have not pr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583253/ https://www.ncbi.nlm.nih.gov/pubmed/33092588 http://dx.doi.org/10.1186/s12933-020-01160-y |
_version_ | 1783599364502978560 |
---|---|
author | Bojer, Annemie Stege Sørensen, Martin Heyn Vejlstrup, Niels Goetze, Jens P. Gæde, Peter Madsen, Per Lav |
author_facet | Bojer, Annemie Stege Sørensen, Martin Heyn Vejlstrup, Niels Goetze, Jens P. Gæde, Peter Madsen, Per Lav |
author_sort | Bojer, Annemie Stege |
collection | PubMed |
description | BACKGROUND: Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in various non-ischemic cardiomyopathies. Ischemic LGE lesions are prevalent in diabetes (DM), but non-ischemic LGE lesions have not previously been described or systematically studied in DM. METHODS: 296 patients with type 2 DM (T2DM) and 25 sex-matched control subjects underwent echocardiography and CMR including adenosine-stress perfusion, T(1)-mapping and LGE. RESULTS: 264 patients and all control subjects completed the CMR protocol. 78.4% of patients with T2DM had no LGE lesions; 11.0% had ischemic LGE lesions only; 9.5% had non-ischemic LGE lesions only; and 1.1% had both one ischemic and one non-ischemic lesion. The non-ischemic LGE lesions were situated mid-myocardial in the basal lateral or the basal inferolateral part of the left ventricle and the affected segments showed normal to high wall thickness and normal contraction. Patients with non-ischemic LGE lesions in comparison with patients without LGE lesions had increased myocardial mass (150 ± 34 vs. 133 ± 33 g, P = 0.02), average E/e’(9.9 IQR8.7–12.6 vs. 8.8 IQR7.4–10.7, P = 0.04), left atrial maximal volume (102 IQR84.6–115.2 vs. 91 IQR75.2–100.0 mL, P = 0.049), NT-proBNP (8.9 IQR5.9–19.7 vs. 5.9 IQR5.9–10.1 µmol/L, P = 0.02) and high-sensitive troponin (15.6 IQR13.0–26.1 vs. 13.0 IQR13.0–14.6 ng/L, P = 0.007) and a higher prevalence of retinopathy (48 vs. 25%, P = 0.009) and autonomic neuropathy (52 vs. 30.5%, P = 0.005). CONCLUSION: A specific LGE pattern with lesions in the basal lateral or the basal inferolateral part of the left ventricle was found in patients with type 2 diabetes. Trial registration https://www.clinicaltrials.gov. Unique identifier: NCT02684331. |
format | Online Article Text |
id | pubmed-7583253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75832532020-10-26 Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes Bojer, Annemie Stege Sørensen, Martin Heyn Vejlstrup, Niels Goetze, Jens P. Gæde, Peter Madsen, Per Lav Cardiovasc Diabetol Original Investigation BACKGROUND: Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in various non-ischemic cardiomyopathies. Ischemic LGE lesions are prevalent in diabetes (DM), but non-ischemic LGE lesions have not previously been described or systematically studied in DM. METHODS: 296 patients with type 2 DM (T2DM) and 25 sex-matched control subjects underwent echocardiography and CMR including adenosine-stress perfusion, T(1)-mapping and LGE. RESULTS: 264 patients and all control subjects completed the CMR protocol. 78.4% of patients with T2DM had no LGE lesions; 11.0% had ischemic LGE lesions only; 9.5% had non-ischemic LGE lesions only; and 1.1% had both one ischemic and one non-ischemic lesion. The non-ischemic LGE lesions were situated mid-myocardial in the basal lateral or the basal inferolateral part of the left ventricle and the affected segments showed normal to high wall thickness and normal contraction. Patients with non-ischemic LGE lesions in comparison with patients without LGE lesions had increased myocardial mass (150 ± 34 vs. 133 ± 33 g, P = 0.02), average E/e’(9.9 IQR8.7–12.6 vs. 8.8 IQR7.4–10.7, P = 0.04), left atrial maximal volume (102 IQR84.6–115.2 vs. 91 IQR75.2–100.0 mL, P = 0.049), NT-proBNP (8.9 IQR5.9–19.7 vs. 5.9 IQR5.9–10.1 µmol/L, P = 0.02) and high-sensitive troponin (15.6 IQR13.0–26.1 vs. 13.0 IQR13.0–14.6 ng/L, P = 0.007) and a higher prevalence of retinopathy (48 vs. 25%, P = 0.009) and autonomic neuropathy (52 vs. 30.5%, P = 0.005). CONCLUSION: A specific LGE pattern with lesions in the basal lateral or the basal inferolateral part of the left ventricle was found in patients with type 2 diabetes. Trial registration https://www.clinicaltrials.gov. Unique identifier: NCT02684331. BioMed Central 2020-10-22 /pmc/articles/PMC7583253/ /pubmed/33092588 http://dx.doi.org/10.1186/s12933-020-01160-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Investigation Bojer, Annemie Stege Sørensen, Martin Heyn Vejlstrup, Niels Goetze, Jens P. Gæde, Peter Madsen, Per Lav Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes |
title | Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes |
title_full | Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes |
title_fullStr | Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes |
title_full_unstemmed | Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes |
title_short | Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes |
title_sort | distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583253/ https://www.ncbi.nlm.nih.gov/pubmed/33092588 http://dx.doi.org/10.1186/s12933-020-01160-y |
work_keys_str_mv | AT bojerannemiestege distinctnonischemicmyocardiallategadoliniumenhancementlesionsinpatientswithtype2diabetes AT sørensenmartinheyn distinctnonischemicmyocardiallategadoliniumenhancementlesionsinpatientswithtype2diabetes AT vejlstrupniels distinctnonischemicmyocardiallategadoliniumenhancementlesionsinpatientswithtype2diabetes AT goetzejensp distinctnonischemicmyocardiallategadoliniumenhancementlesionsinpatientswithtype2diabetes AT gædepeter distinctnonischemicmyocardiallategadoliniumenhancementlesionsinpatientswithtype2diabetes AT madsenperlav distinctnonischemicmyocardiallategadoliniumenhancementlesionsinpatientswithtype2diabetes |